193 related articles for article (PubMed ID: 1363199)
21. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
[TBL] [Abstract][Full Text] [Related]
24. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G
J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
[TBL] [Abstract][Full Text] [Related]
25. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
[TBL] [Abstract][Full Text] [Related]
26. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
Boesch D; Loor F
Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109
[TBL] [Abstract][Full Text] [Related]
27. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
29. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
[TBL] [Abstract][Full Text] [Related]
30. Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma.
Tong AW; Su D; Mues G; Tillery GW; Goldstein R; Klintmalm G; Stone MJ
Clin Cancer Res; 1996 Mar; 2(3):531-9. PubMed ID: 9816200
[TBL] [Abstract][Full Text] [Related]
31. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Salmon SE; Dalton WS; Grogan TM; Plezia P; Lehnert M; Roe DJ; Miller TP
Blood; 1991 Jul; 78(1):44-50. PubMed ID: 1676918
[TBL] [Abstract][Full Text] [Related]
32. Myeloid and lymphoid cell alterations in normal mice exposed to chemotherapy with doxorubicin and/or the multidrug-resistance reversing agent SDZ PSC 833.
Froidevaux S; Loor F
Int J Cancer; 1994 Oct; 59(1):133-40. PubMed ID: 7927893
[TBL] [Abstract][Full Text] [Related]
33. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor.
Didier A; Loor F
Anticancer Drugs; 1996 Sep; 7(7):745-51. PubMed ID: 8949985
[TBL] [Abstract][Full Text] [Related]
34. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
35. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
36. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.
Watanabe T; Tsuge H; Oh-Hara T; Naito M; Tsuruo T
Acta Oncol; 1995; 34(2):235-41. PubMed ID: 7718262
[TBL] [Abstract][Full Text] [Related]
37. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Lehne G; De Angelis P; den Boer M; Rugstad HE
Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.
Van de Vrie W; Gheuens EE; Durante NM; De Bruijn EA; Marquet RL; Van Oosterom AT; Eggermont AM
J Cancer Res Clin Oncol; 1993; 119(10):609-14. PubMed ID: 8101524
[TBL] [Abstract][Full Text] [Related]
39. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
[TBL] [Abstract][Full Text] [Related]
40. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Nissen NI
Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
